DEPARTMENT OF PHARMACOLOGY





 

 

Research schemes

Details about Ongoing projects during the year

  1. Clinical training Research Centre Funding agency DBT (Dr. Uma Tekur)
  2. Essential drug concept as a code of drug policy impact on drug availability, affordability of quality drug & their rational use (Dr. Vandana Roy)
  3. Knowledge, attitude & perception towards use of complementary and alternative medicines in sample population of an Indian Metropolis (Dr. Vandana Roy, Dr. Pooja Chatley)
  4. Monitoring of Adverse Drug Reactions Department of Pharmacology, MAMC is Peripheral Pharmacovigilance Centre (Dr. Shalini Chawla)

Trainees from other agencies

Mr. Mohit Dubey from St. Lawrence Pharmacy College, 3rd Year student, I.P. University.

Training courses/ conferences/ workshops organized  :          Nil

Publication of research papers in journal during the period
  1. Journal Publication (Indexed Journal)

    1. P Gupta, Vandana Roy, G. R. Sethi, T.K. Mishra-Pyrazinamide blood levels in children suffering from tuberculosis: A comparative study at two doses, British Journal of Clinical Pharmacology accepted Nov. 2007.
    2. Vandana Tayal, Bhupinder Singh Kalra, Sarita Agarwal, Nita Khurana & Usha Gupta. Hepatoprotective effect of tocopherol against isoniazid and rifampicin induced hepatotoxicity in albino rabbits. Ind J Exp Biol ; 45, 2007, 1031-1036.
    3. Vandana Tayal & Bhupinder Singh kalra. Cytokines and anticytokines as therapeutics –as update. Eur J Pharmacol. Oct 25 [ EPub ahead of print], 2007.

  2. Journal Publication ( Non Indexed Journal

    1. Vandana Roy Pharmacology for Dental students in India a need for changed. Indian association times 4:11May 2007
    2. Vandana Tayal & Bhupinder Singh kalra. Aliskiren : A novel rennin inhibitor for hypertension. Current Drug Therapy. 2(3), 2007, 236-239.
    3. Bhupinder Singh Kalra & Vandana Tayal. Darusentan: A promising drug for resistant hypertension JIMSA. 20(3): 2007, 245.
    4. Somnath Datta, Vandana Tayal, Nirmal Kumar, Shalini Chawla. Life threatening hyperkalemia and acute renal failure due to ACE inhibition (abstract). Journal of pharmacovigilance and drug safety, 5; 2007, 125.